LONDON and PHILADELPHIA – May 13, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces it has issued and allotted a total 1,604,063 new ordinary shares of 10 pence each in the Company (“New Ordinary Shares”).
The New Ordinary Shares are being issued in settlement of a Notice of Conversion for £1.20 million of the principal amount of the Company’s unsecured convertible bond (the “Conversion”).
As a result of the Conversion, the principal remaining under the convertible bond will be reduced by £1.20 million to £19.20 million.
Admission and Total Voting Rights
Application has been made to AIM for the admission to trading of the 1,604,063 New Ordinary Shares to trading on AIM (“Admission”). It is expected Admission will become effective and dealings in such Ordinary Shares will commence at 8.00 am on or around 18 May 2026. The New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Immediately following Admission, the Company’s enlarged issued share capital will be 457,892,574 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.